Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GAO and nutritionals

This article was originally published in The Tan Sheet

Executive Summary

Report examining existing federal mechanisms for ensuring the safety of supplements and functional foods and the accuracy of their labeling/advertising claims is slated for July release. The analysis, a self-initiated project by the General Accounting Office, was spurred by consumer interest and growth in the industry. The analysis will incorporate data from approximately two dozen entities, including FDA, NIH, FTC, the California Department of Health, trade groups, nutrition and consumer groups, academia and six food companies. GAO's August 1999 report questioning FDA's reliance on AER data to support a proposed rule restricting the use of ephedrine alkaloids in supplements was a key factor in the agency's recent withdrawal of the proposed reg's dosing and duration of use limits (1"The Tan Sheet" March 6, p. 9)

You may also be interested in...



Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input

FDA will consider "public comment of the widest kind" from the "layperson to health professionals to scientists" in analyzing and changing portions of the June 1997 proposed rule on ephedrine alkaloids in dietary supplements, Commissioner Jane Henney, MD, testified at a congressional hearing Feb. 29.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel